Many early-career researchers would jump at the chance to join a project with a large team of accomplished scientists — but could that move backfire? As Jonathan Wosen, PhD of STAT highlighted this week, recent research suggests that increasingly large scientific teams can hamper career advancement for early career researchers — potentially contributing to an ongoing exodus from academic research. Part of the problem? Publications by large teams can obscure the contributions of more junior scientists. This challenge is real — but abandoning team science isn’t the answer. Instead, the research community needs new approaches, such as one pioneered by The Mark Foundation with our Endeavor Award program. https://lnkd.in/eSZZUPXX Here’s what makes the Endeavor Awards unique: -We welcome new teams who haven’t worked together previously -We encourage high-risk ideas (& don’t require years of prelim data) -We allow junior scientists to lead research teams Our selection process rewards true team projects: members collaborate on the same question, each contributing unique expertise instead of working separately on similar topics. This encourages mentorship & gives junior scientists greater access to their senior counterparts. Through Endeavor, we’ve seen researchers like Tullia Bruno, Semir Beyaz, Tobias Janowitz, & Rob Welner take on leadership roles, making remarkable strides forward in their careers & meaningful progress on major #cancerresearch challenges. Continued scientific progress requires a strong pipeline of talent. By adapting grant structures and opening up more opportunities for early-career researchers to lead, we can tackle that challenge and benefit from the ideas & insights of scientists at every career stage. What are your thoughts on the rise of large scientific teams and how they impact career development? Let us know in the comments! https://lnkd.in/en_zByAf
The Mark Foundation for Cancer Research
Research Services
New York, NY 2,103 followers
Partnering with scientists to accelerate transformation in cancer research
About us
The Mark Foundation for Cancer Research actively partners with scientists to accelerate research that will transform the prevention, diagnosis, and treatment of cancer. We fulfill our mission by supporting groundbreaking science carried out by individual investigators, multi-disciplinary teams, and inter-institutional collaborations in the United States and across the globe. Recognizing the obstacles that prevent scientific advances from improving patient outcomes, we maintain a nimble, high-impact approach to funding research through grants for basic and translational cancer research and venture investments in early-stage companies that bridge the gap between bench and bedside.
- Website
-
http://themarkfoundation.org/
External link for The Mark Foundation for Cancer Research
- Industry
- Research Services
- Company size
- 2-10 employees
- Headquarters
- New York, NY
- Type
- Nonprofit
- Founded
- 2015
- Specialties
- cancer research
Locations
-
Primary
New York, NY 10019, US
Employees at The Mark Foundation for Cancer Research
-
Pamela Carroll
Life Science Executive l Entrepreneur l AI-driven Drug Discovery l COO l CBO I R&D Leader
-
Xiaoxiao (Vany) Sun
UCSF Researcher
-
Nicola Mendelsohn CBE
Head of Global Business Group at Meta
-
Ray DuBois
Director: MUSC Hollings Cancer Center, Associate Provost for Cancer Programs at MUSC & Executive Chair of the Mark Foundation for Cancer Research…
Updates
-
On Monday, we visited The Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation at the University of Pennsylvania to hear the latest from the Center’s director Andy Minn and team members Sara Cherry, Carl June, Costas Koumenis, & E. John Wherry. The Center, founded in 2019, is working to modulate immune signaling pathways for better cancer treatments. Most recently, the team showed that adding JAK inhibitors to anti–PD–1 immunotherapy improves outcomes for patients with non-small cell lung cancer. https://lnkd.in/eUzbqEmi
-
-
In a new paper in the Journal of Clinical Oncology, Michael Jain of the Moffitt Cancer Center reports key findings from a 5-year study on long-term outcomes following CAR T cell therapy in #lymphoma, work partly funded by a multi-center Mark Foundation Endeavor Award. https://lnkd.in/edWC3NRi
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium | Journal of Clinical Oncology
ascopubs.org
-
Can aspirin help prevent colorectal cancer? In a new JAMA Oncology paper, Daniel Sikavi of Massachusetts General Hospital shows that regular aspirin use may reduce the incidence of colorectal cancer, especially among individuals with other risk factors. Mark Foundation Board Chair Ray DuBois weighed in on the research on CNN, noting, “We try as hard as we can to get people in a healthier state, but in some people, it’s just very difficult to lose weight or quit smoking. This could be a simple option that could help, especially for those who are at highest risk.” https://lnkd.in/eK76eWtP
-
-
No two cases of multiple myeloma are alike — and that makes treatment decisions a challenge. In Nature Portfolio's NPJ Digital Medicine, ASPIRE awardee David Sontag of Massachusetts Institute of Technology introduces a transformer-based machine-learning model to help physicians estimate disease progression and predict treatment outcomes. #PrecisionMedicine #MachineLearning https://lnkd.in/enmyh49e
-
-
Chromosomal instability is present in 60–80% of cancers, but it isn’t directly targeted by any current treatments. In Nature Portfolio's Nature Reviews Clinical Oncology, Emerging Leader Award winner Samuel Bakhoum of Memorial Sloan Kettering Cancer Center highlights recent advances in our understanding of chromosomal instability that could lead to therapies for difficult-to-treat cancers. https://lnkd.in/eFEdxE6g
Targeting chromosomal instability in patients with cancer - Nature Reviews Clinical Oncology
nature.com
-
Mark Foundation-funded investigators are on a roll! In the second quarter of 2024, our grantees published 15 papers including Nature, Science, Nature Medicine, and more. Topics ranged from new therapeutic approaches to methods for high-dimensional tissue imaging, with papers by grantees including Andrew Lane, MD, PhD, Andy Minn, Dan-Avi Landau, Tobias Janowitz, Gregory Beatty, Hao Zhu, Jeffrey Rathmell, Alyssa Hasty, Kathryn Wellen, Jennifer Munkley, Kara Davis, Kivanç Birsoy, Margaret Shipp, Mihaela Angelova, and Robert Bradley. Read the papers: https://lnkd.in/gKZ2F79F
Research Spotlight: Mark Foundation-Supported Cancer Research Advances in Q2 2024
https://themarkfoundation.org
-
“Our main purpose is to fund the very best science that will have the biggest impact on the field.” Learn how The Mark Foundation is shaping the future of cancer care on the latest Believe in Progress podcast from the American Association for Cancer Research. In the episode, our CEO Ryan Schoenfeld and Chair Ray DuBois discuss global collaborations, interdisciplinary research, and the cancer research trends they're watching. Listen on your favorite podcast app, or watch a video of their interview at the link below! https://lnkd.in/eNZGSzqY
-
-
In 30 years, survival rates for kids with solid tumors have barely changed. That's why we're supporting the NexTGen Cancer Grand Challenges team with Cancer Research UK (CRUK) and the National Cancer Institute (NCI). The team, led by Catherine Bollard at Children's National Hospital and Martin Pule at University College London Hospitals NHS Foundation Trust, is working to develop and optimize novel CAR T-cell therapies for pediatric sarcomas and brain tumors. #SarcomaAwarenessMonth https://lnkd.in/efyKu-G4
-
-
🎉 We're proud to announce the recipients of this year's Momentum Fellowships! 🎉 ⭐Mihaela Angelova, PhD, The Francis Crick Institute ⭐Leire Bejarano Bosque, PhD, University of Lausanne - UNIL Ludwig Institute for Cancer Research ⭐Thang Do Cong, PhD, University of California, Berkeley ⭐Pablo Riera Freire, PhD, Dana-Farber Cancer Institute Cancer Institute ⭐Elizabeth A R Garfinkle, PhD, Nationwide Children's Hospital ⭐Stephanie Gomez, PhD, Children's National Hospital ⭐Júlia Matas Gironella, PhD, Peter MacCallum Cancer Centre, The University of Melbourne ⭐Vera Tiedje, MD, PhD, Memorial Sloan Kettering Cancer Center ⭐Ping Wang, PhD, University of Pennsylvania These promising investigators are pushing boundaries with work on tumor microenvironment evolution, tumor vasculature analysis, transcription factor degradation, and more.🔬🧬 Congratulations, all — we look forward to watching your work develop! https://lnkd.in/eFsnvTeb
-